Tridek-One, Paris, November 25, 2019 – Tridek One, a biotech company specialized in the development of products for the treatment of immune disorders, announces today the appointment of Régis Olivier as Chief Executive Officer. He replaces Philippe Berthon.
Régis Olivier has joined the company in april 2019 as Chief Financial Officer.
Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, together with Advent France Biotechnology, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions. Tridek-One has recently announced a 3M€ funding supported by two venture funds, Advent France Biotechnology and Advent Life Sciences (UK). For more information, please visit www.tridekone.com
About Advent France Biotechnology
Advent France Biotechnology is a French Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward. The firm works with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. Advent France Biotechnology Seed Fund I stands as the first dedicated Life Sciences seed-fund in France. For more information, please visit www.adventfb.com
Advent Life Sciences (UK)
Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. The team consists of professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies and med tech. For more information, please visit www.adventls.com.